[Effectiveness of hearing aid provision for severe hearing loss]

[助听器对重度听力损失的有效性]

阅读:2

Abstract

BACKGROUND AND OBJECTIVE: In practice, the unilateral monosyllabic speech recognition score with hearing aid (WRS(65)(HA)) is often below the maximum word recognition score with headphones (WRS(max)), in particular for subjects with severe hearing loss. The aim of this study was to evaluate the efficiency factor Q of hearing aid provision, the ratio WRS(65)(HA)/WRS(max), in patients with severe to profound hearing loss. MATERIALS AND METHODS: Data from real-ear measurements (REM), pure tone and speech audiogram, and speech recognition with and without hearing aid of 93 ears in 64 patients were examined. The patients visited the authors' hearing center for hearing aid evaluation in 2019. Deviations of the real-ear measured frequency-dependent output level values from the prescription targets NAL-NL2 and DSL v5.0 were analyzed. Spearman correlation coefficients for the speech intelligibility index (SII) were calculated for the parameters WRS(65)(HA) and Q. RESULTS: In more than 67% of the hearing aid fittings, output level values matched the target curves of NAL-NL2 or DSL v5.0 in the range of ±5 dB for frequencies from 0.5 to 4 kHz at 65 dB SPL. Nevertheless, WRS(max) was not achieved with hearing aid at conversational speech levels of 65 dB SPL (mean deviations: 34.4%). However, WRS(65)(HA) and Q were best when target values for DSL v5.0 were achieved at 65 dB SPL, which is associated with a higher SII. CONCLUSION: For patients with severe to profound hearing loss, the prescription targets of NAL-NL2 and DSL v5.0 do not provide sufficient amplification for WRS(max) to be achieved at a normal speech level of 65 dB SPL. It remains to be investigated whether alternative prescriptions with better audibility for input levels of 50 and 65 dB SPL might improve the effectiveness of hearing aid provision.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。